thalidomide has been researched along with Anemia, Macrocytic in 32 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Anemia, Macrocytic: Anemia characterized by larger than normal erythrocytes, increased mean corpuscular volume (MCV) and increased mean corpuscular hemoglobin (MCH).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with deletion 5q cytogenetic abnormality, as part of the Institute's single technology appraisal (STA) process." | 7.83 | Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. ( Al, MJ; Armstrong, N; Blommestein, HM; Deshpande, S; Kleijnen, J; Noake, C; Riemsma, R; Ryder, S; Severens, JL; Worthy, G, 2016) |
| "We present the case of a 71-year-old woman with a long-standing history of refractory pulmonary sarcoidosis, who, upon commencement of treatment with lenalidomide for her newly diagnosed 5q-myelodysplastic syndrome, showed a remarkable, immediate, unexpected response and recovery of her sarcoidosis-related symptoms, improvement of her vital capacity, and complete clearance of her bibasal alveolor infiltrates." | 7.81 | Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis. ( Bazargan, A; Giv, MJ; Yoosuff, A, 2015) |
| "Lenalidomide treatment may be effective in improving HRQL outcomes." | 6.78 | Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. ( Brandenburg, NA; Fenaux, P; Knight, R; Muus, P; Revicki, DA; Yu, R, 2013) |
| " Safety was evaluated based on the occurrence rates of grades 3-4 adverse events (AEs)." | 6.53 | Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis. ( Deng, ZQ; He, PF; Lian, XY; Lin, J; Qian, J; Wen, XM; Xu, ZJ; Yang, L; Yao, DM; Zhang, ZH, 2016) |
| " The most common adverse events (incidence ≥20 %) occurring in lenalidomide recipients were thrombocytopenia and neutropenia, which were generally managed by dosage reductions and/or interruptions, and/or pharmacotherapy." | 6.49 | Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion. ( Scott, LJ; Syed, YY, 2013) |
| "The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with deletion 5q cytogenetic abnormality, as part of the Institute's single technology appraisal (STA) process." | 3.83 | Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. ( Al, MJ; Armstrong, N; Blommestein, HM; Deshpande, S; Kleijnen, J; Noake, C; Riemsma, R; Ryder, S; Severens, JL; Worthy, G, 2016) |
| "We present the case of a 71-year-old woman with a long-standing history of refractory pulmonary sarcoidosis, who, upon commencement of treatment with lenalidomide for her newly diagnosed 5q-myelodysplastic syndrome, showed a remarkable, immediate, unexpected response and recovery of her sarcoidosis-related symptoms, improvement of her vital capacity, and complete clearance of her bibasal alveolor infiltrates." | 3.81 | Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis. ( Bazargan, A; Giv, MJ; Yoosuff, A, 2015) |
| "Lenalidomide has demonstrated remarkable efficacy for therapy of lower-risk myelodysplastic syndromes (MDS) associated with 5q(-)." | 3.81 | Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. ( Aschauer, G; Burgstaller, S; Fiegl, M; Fridrik, M; Girschikofsky, M; Greil, R; Keil, F; Linkesch, W; Nösslinger, T; Petzer, A; Stauder, R, 2015) |
| " Although lenalidomide therapy was initiated, it had to be discontinued because of Stevens-Johnson syndrome, which occurred during the second course of treatment." | 3.79 | [A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts]. ( Abe, T; Arihara, Y; Fujii, S; Fujita, M; Hirako, T; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Miura, S; Nagashima, K; Sakurai, T; Yamada, M; Yoshida, M, 2013) |
| "Lenalidomide treatment may be effective in improving HRQL outcomes." | 2.78 | Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. ( Brandenburg, NA; Fenaux, P; Knight, R; Muus, P; Revicki, DA; Yu, R, 2013) |
| " Safety was evaluated based on the occurrence rates of grades 3-4 adverse events (AEs)." | 2.53 | Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis. ( Deng, ZQ; He, PF; Lian, XY; Lin, J; Qian, J; Wen, XM; Xu, ZJ; Yang, L; Yao, DM; Zhang, ZH, 2016) |
| " The most common adverse events (incidence ≥20 %) occurring in lenalidomide recipients were thrombocytopenia and neutropenia, which were generally managed by dosage reductions and/or interruptions, and/or pharmacotherapy." | 2.49 | Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion. ( Scott, LJ; Syed, YY, 2013) |
| "Lenalidomide is a potent drug with pleiotropic effects in patients with myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 5 [del(5q)]." | 1.42 | Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide. ( Belickova, M; Cermak, J; Hrustincova, A; Jonasova, A; Klema, J; Krejcik, Z; Merkerova, MD; Michalova, K; Stara, E; Zemanova, Z, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 30 (93.75) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Sakai, H | 1 |
| Miura, I | 1 |
| Arai, A | 1 |
| Palacios-Campos, A | 1 |
| Gutierrez, O | 1 |
| Fabian-Morales, E | 1 |
| Avilés, A | 1 |
| Candelaria, M | 1 |
| Syed, YY | 1 |
| Scott, LJ | 1 |
| Ortega, M | 1 |
| Mallo, M | 1 |
| Solé, F | 1 |
| Sánchez-Morata, C | 1 |
| López-Andreoni, L | 1 |
| Martínez-Morgado, N | 1 |
| Gironella, M | 1 |
| Valcárcel, D | 1 |
| Vallespí, T | 1 |
| Vlachos, A | 1 |
| Farrar, JE | 1 |
| Atsidaftos, E | 1 |
| Muir, E | 1 |
| Narla, A | 1 |
| Markello, TC | 1 |
| Singh, SA | 1 |
| Landowski, M | 1 |
| Gazda, HT | 1 |
| Blanc, L | 1 |
| Liu, JM | 1 |
| Ellis, SR | 1 |
| Arceci, RJ | 1 |
| Ebert, BL | 1 |
| Bodine, DM | 1 |
| Lipton, JM | 1 |
| Vigna, E | 1 |
| Recchia, AG | 1 |
| Cuzzola, M | 2 |
| Morabito, L | 1 |
| Gentile, M | 1 |
| Morabito, F | 2 |
| Yamada, M | 1 |
| Kuroda, H | 1 |
| Jomen, W | 1 |
| Yoshida, M | 1 |
| Miura, S | 1 |
| Abe, T | 1 |
| Sakurai, T | 1 |
| Fujii, S | 1 |
| Maeda, M | 1 |
| Fujita, M | 1 |
| Nagashima, K | 1 |
| Arihara, Y | 1 |
| Hirako, T | 1 |
| Kato, J | 1 |
| Jonasova, A | 3 |
| Bokorova, R | 1 |
| Polak, J | 1 |
| Vostry, M | 1 |
| Kostecka, A | 1 |
| Hajkova, H | 1 |
| Neuwirtova, R | 1 |
| Siskova, M | 1 |
| Sponerova, D | 1 |
| Cermak, J | 2 |
| Mikulenkova, D | 1 |
| Cervinek, L | 1 |
| Brezinova, J | 1 |
| Michalova, K | 2 |
| Fuchs, O | 1 |
| Merkerova, MD | 1 |
| Krejcik, Z | 1 |
| Belickova, M | 1 |
| Hrustincova, A | 1 |
| Klema, J | 1 |
| Stara, E | 1 |
| Zemanova, Z | 1 |
| Messingerová, L | 1 |
| Barančik, M | 1 |
| Poleková, L | 1 |
| Šereš, M | 1 |
| Gibalová, L | 1 |
| Breier, A | 1 |
| Sulová, Z | 1 |
| Giv, MJ | 2 |
| Yoosuff, A | 1 |
| Bazargan, A | 2 |
| Blommestein, HM | 1 |
| Armstrong, N | 1 |
| Ryder, S | 1 |
| Deshpande, S | 1 |
| Worthy, G | 1 |
| Noake, C | 1 |
| Riemsma, R | 1 |
| Kleijnen, J | 1 |
| Severens, JL | 1 |
| Al, MJ | 1 |
| Aschauer, G | 1 |
| Greil, R | 1 |
| Linkesch, W | 1 |
| Nösslinger, T | 1 |
| Stauder, R | 1 |
| Burgstaller, S | 1 |
| Fiegl, M | 1 |
| Fridrik, M | 1 |
| Girschikofsky, M | 1 |
| Keil, F | 1 |
| Petzer, A | 1 |
| Sahu, KK | 1 |
| Varma, SC | 1 |
| Chesnais, V | 1 |
| Renneville, A | 1 |
| Toma, A | 1 |
| Lambert, J | 1 |
| Passet, M | 1 |
| Dumont, F | 1 |
| Chevret, S | 1 |
| Lejeune, J | 1 |
| Raimbault, A | 1 |
| Stamatoullas, A | 1 |
| Rose, C | 1 |
| Beyne-Rauzy, O | 1 |
| Delaunay, J | 1 |
| Solary, E | 1 |
| Fenaux, P | 2 |
| Dreyfus, F | 1 |
| Preudhomme, C | 1 |
| Kosmider, O | 1 |
| Fontenay, M | 1 |
| Wells, RA | 1 |
| Buckstein, R | 1 |
| Rezmovitz, J | 1 |
| Balaian, E | 1 |
| Schuster, C | 1 |
| Schönefeldt, C | 1 |
| Germing, U | 1 |
| Haase, D | 1 |
| Tuve, S | 1 |
| Ordemann, R | 1 |
| Ehninger, G | 1 |
| Bornhäuser, M | 1 |
| Oelschlaegel, U | 1 |
| Mohr, B | 1 |
| von Bonin, M | 1 |
| Platzbecker, U | 1 |
| Wermke, M | 1 |
| Lian, XY | 1 |
| Zhang, ZH | 1 |
| Deng, ZQ | 1 |
| He, PF | 1 |
| Yao, DM | 1 |
| Xu, ZJ | 1 |
| Wen, XM | 1 |
| Yang, L | 1 |
| Lin, J | 1 |
| Qian, J | 1 |
| Ureshino, H | 1 |
| Kizuka, H | 1 |
| Kusaba, K | 1 |
| Sano, H | 1 |
| Nishioka, A | 1 |
| Shindo, T | 1 |
| Kubota, Y | 1 |
| Ando, T | 1 |
| Kojima, K | 1 |
| Kimura, S | 1 |
| Ziarkiewicz, M | 1 |
| Dwilewicz-Trojaczek, J | 1 |
| Pastwińska, A | 1 |
| Chmarzyńska, E | 1 |
| Paszkowska-Kowalewska, M | 1 |
| Koperski, Ł | 1 |
| Jędrzejczak, WW | 1 |
| Ziarkiewicz-Wróblewska, B | 1 |
| Padron, E | 2 |
| Komrokji, R | 2 |
| List, AF | 3 |
| Breccia, M | 2 |
| Cannella, L | 1 |
| Latagliata, R | 2 |
| Loglisci, G | 1 |
| Salaroli, A | 1 |
| Santopietro, M | 1 |
| Oliva, EN | 2 |
| Alimena, G | 2 |
| Sanchez, JF | 1 |
| Nomdedeu, M | 1 |
| Maffioli, M | 1 |
| Calvo, X | 1 |
| Martínez-Trillos, A | 1 |
| Baumann, T | 1 |
| Díaz-Beyá, M | 1 |
| Aguilar, JL | 1 |
| Rozman, M | 1 |
| Costa, D | 1 |
| Esteve, J | 1 |
| Cervantes, F | 1 |
| Colomer, D | 1 |
| Nomdedeu, B | 1 |
| Katayama, Y | 1 |
| Komrokji, RS | 1 |
| Keel, SB | 1 |
| Phelps, S | 1 |
| Sabo, KM | 1 |
| O'Leary, MN | 1 |
| Kirn-Safran, CB | 1 |
| Abkowitz, JL | 1 |
| Aloe Spiriti, MA | 1 |
| Poloni, A | 1 |
| Laganà, C | 1 |
| Rigolino, C | 1 |
| Galimberti, S | 1 |
| Ghio, R | 1 |
| Cortelezzi, A | 1 |
| Palumbo, GA | 1 |
| Sanpaolo, G | 1 |
| Finelli, C | 1 |
| Ricco, A | 1 |
| Volpe, A | 1 |
| Rodà, F | 1 |
| Nobile, F | 1 |
| Liu, D | 1 |
| Chen, S | 1 |
| Pan, J | 1 |
| Zhu, M | 1 |
| Wu, N | 1 |
| Zhu, F | 1 |
| Chen, Z | 1 |
| Revicki, DA | 1 |
| Brandenburg, NA | 1 |
| Muus, P | 1 |
| Yu, R | 1 |
| Knight, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diamond Blackfan Anemia Registry (DBAR)[NCT00106015] | 900 participants (Anticipated) | Observational | 2004-09-30 | Recruiting | |||
| A Phase II Study Evaluating the Efficacy/Safety of Lenalidomide With or Without Epoetin Beta in Transfusion-dependent ESA-resistant Patients With IPSS Low- and Intermediate-1 Risk Myelodysplastic Syndromes Without Chromosome 5 Abnormality.[NCT01718379] | Phase 2 | 132 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Salvage in Patients With Myelodysplastic Syndrome After Failure of Hypomethylating Agents: Lenalidomide as a Second-line Therapy[NCT01673308] | Phase 2 | 35 participants (Anticipated) | Interventional | 2012-08-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for thalidomide and Anemia, Macrocytic
| Article | Year |
|---|---|
Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
Topics: Anemia; Anemia, Macrocytic; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5 | 2013 |
Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
Topics: Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Immunologic Factors; Le | 2016 |
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromo | 2017 |
Biology and treatment of the 5q- syndrome.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical | 2011 |
Treatment of myelodysplastic syndromes in elderly patients.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Agents; Azacitidine; Blood Component Transfusion; Case Mana | 2011 |
[Molecular mechanisms of lenalidomide for the treatment of myelodysplastic syndromes].
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Genes, p | 2011 |
Role of lenalidomide in the treatment of myelodysplastic syndromes.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical | 2011 |
5 trials available for thalidomide and Anemia, Macrocytic
| Article | Year |
|---|---|
Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.
Topics: Adult; Aged; Anemia, Macrocytic; Biomarkers; Blood Proteins; Chromosome Deletion; Chromosomes, Human | 2015 |
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Chromo | 2016 |
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.
Topics: Aged; Aged, 80 and over; Anemia, Macrocytic; Bone Marrow; Chromosome Deletion; Chromosomes, Human, P | 2016 |
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.
Topics: Aged; Anemia, Macrocytic; Apoptosis; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pai | 2013 |
Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antineoplastic Agents; Blood Transfusion; Chromo | 2013 |
20 other studies available for thalidomide and Anemia, Macrocytic
| Article | Year |
|---|---|
Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome.
Topics: Aged, 80 and over; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Cri-du-Chat | 2022 |
Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case.
Topics: Aged; Anemia, Macrocytic; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; | 2020 |
5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.
Topics: Abnormal Karyotype; Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Chromo | 2013 |
Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q- syndrome.
Topics: Adolescent; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Child, Preschool; Chromosome Deletion; Chr | 2013 |
Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?
Topics: Aged; Anemia, Macrocytic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 5; Deferasirox; E | 2014 |
[A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts].
Topics: Aged, 80 and over; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Fatal Outcom | 2013 |
High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Topics: Adaptor Proteins, Signal Transducing; Anemia, Macrocytic; Case-Control Studies; Chromosome Deletion; | 2015 |
Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Topics: Aged; Anemia, Macrocytic; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 14; Ch | 2015 |
Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis.
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunolog | 2015 |
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
Topics: Anemia, Macrocytic; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cost-Be | 2016 |
Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Angiogenesis Inhibitors; Austria; Chromosome Abe | 2015 |
Lenalidomide in Nonmalignant Disorders: A New Ray of Hope for Refractory Sarcoidosis.
Topics: Anemia, Macrocytic; Female; Humans; Immunologic Factors; Lung; Radiography; Sarcoidosis, Pulmonary; | 2015 |
Response.
Topics: Anemia, Macrocytic; Female; Humans; Immunologic Factors; Lung; Radiography; Sarcoidosis, Pulmonary; | 2015 |
Myelodysplastic syndrome.
Topics: Aged; Anemia, Macrocytic; Bone Marrow; Erythropoietin; Fatigue; Humans; Lenalidomide; Myelodysplasti | 2016 |
Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
Topics: Aged; Anemia, Macrocytic; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Bone Mar | 2010 |
Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome.
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Erythroid C | 2011 |
Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Topics: Amino Acid Substitution; Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes | 2011 |
The 5q- syndrome: biology and treatment.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; | 2011 |
Establishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis.
Topics: Agranulocytosis; Alleles; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Animals; Chromosome Deletion | 2012 |
Acquired EVI1 rearrangement involved in the transformation from 5q- syndrome to pre-B lymphocytic leukemia in a Chinese patient.
Topics: Adult; Anemia, Macrocytic; Blood Transfusion; Bone Marrow; Cell Differentiation; Cell Lineage; Chrom | 2012 |